Veradermics to Hold Conference Call to Discuss 12-Month Long-Term Results from Phase 3 ‘302’ Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

NEW HAVEN, Conn.–(BUSINESS WIRE)–Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, November 9, 2026, at 8:00 am ET to review topline results from Part B of its randomized, double-blind, placebo-controlled registration-directed Phase 3 clinical trial (Study ‘302’) evaluating VDPHL01, a proprietary, ext

Please leave this field empty

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.

Please check your Inbox or Spam folder now to confirm your subscription.